Covid-19: Bharat Biotech’s Covaxin gets nod for phase three trial
Bharat Biotech's Covaxin gets a nod for its phase three trial in India. The vaccine is created by ICMR and Bharat Biotech and the permission for phase three clinical trial has been granted. According to the sources, 22,000 volunteers have enrolled for the trial and the trials will be conducted in almost 18-19 sites.
The trials of the first two phases were conducted at 12 sites across India for almost 2 months. This is the first indigenous vaccine of India which is going for the clinical trials. The clinical trials of Covaxin are likely to begin in November.